RSV, Pfizer

US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
RSV Vaccine Tied to Fewer Hospitalizations, ED Visits in Older, High-Risk Adults
The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) visits in older patients during the first season of the vaccine's rollout, according to a retrospective analysis.
Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59
The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste
Pfizer announces FDA approval of Abrysvo
Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
Pneumonia can be a deadly complication of COVID, the flu, and RSV. What to know about pneumococcal vaccination
Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious ...
Doctor clears up confusion over Covid, flu and RSV jabs as cases rise
Up to 10,000 Brits a day are getting a new variant of coronavirus called XEC, which is a mixture of the Delta and Omicron ...
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...
dermatologyadvisor17h
Investigational RSV Vaccine mRNA-1345: Revaccination Safe in Eligible Older Adults
Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...
ConsumerAffairs7d
RSV gets no respect although it is a common virus and can be severe
RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren ...
News Medical on MSN2d
Real world data highlights effectiveness of RSV vaccine
A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- ...
Merck's RSV antibody for infants effective in reducing some types of infections in study
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
WDRB11h
Local doctors prepare for busy sick season of flu, COVID, RSV cases
The U.S. Centers for Disease Control and Prevention recommends anyone age six months and older get vaccinated for flu and COVID. Adults age 75 and older, as well as pregnant women, are encouraged to ...
The Columbian1d
WA could be better protected against RSV this winter. Here’s why
Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.
cidrap.umn20h
Genomic surveillance tracks RSV evolution, identifies mutations in Minnesota
A new study shows that the addition of respiratory syncytial virus (RSV) to Minnesota’s viral genomic surveillance program ...